The association between COPD and heart failure risk: a review

Javier de Miguel Díez, Jorge Chancafe Morgan, Rodrigo Jiménez García, Javier de Miguel Díez, Jorge Chancafe Morgan, Rodrigo Jiménez García

Abstract

Chronic obstructive pulmonary disease (COPD) is commonly associated with heart failure (HF) in clinical practice since they share the same pathogenic mechanism. Both conditions incur significant morbidity and mortality. Therefore, the prognosis of COPD and HF combined is poorer than for either disease alone. Nevertheless, usually only one of them is diagnosed. An active search for each condition using clinical examination and additional tests including plasma natriuretic peptides, lung function testing, and echocardiography should be obtained. The combination of COPD and HF presents many therapeutic challenges. The beneficial effects of selective β1-blockers should not be denied in stable patients who have HF and coexisting COPD. Additionally, statins, angiotensin-converting enzyme inhibitors, and angiotensin-receptor blockers may reduce the morbidity and mortality of COPD patients. Moreover, caution is advised with use of inhaled β2-agonists for the treatment of COPD in patients with HF. Finally, noninvasive ventilation, added to conventional therapy, improves the outcome of patients with acute respiratory failure due to hypercapnic exacerbation of COPD or HF in situations of acute pulmonary edema. The establishment of a combined and integrated approach to managing these comorbidities would seem an appropriate strategy. Additional studies providing new data on the pathogenesis and management of patients with COPD and HF are needed, with the purpose of trying to improve quality of life as well as survival of these patients.

Keywords: chronic obstructive pulmonary disease; heart failure.

Figures

Figure 1
Figure 1
Lung inflammation in chronic obstructive pulmonary disease may contribute to the appearance of cardiovascular events. Abbreviations: COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α.

References

    1. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2007;49(2):171–180.
    1. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JV. Heart failure and chronic obstructive pulmonary disease: diagnosis pitfalls and epidemiology. Eur J Heart Fail. 2009;11(2):130–139.
    1. Ni H, Nauman D, Hershberger RE. Managed care and outcomes of hospitalization among elderly patients with congestive heart failure. Arch Intern Med. 1998;158(11):1231–1236.
    1. Lainscak M, Hodoscek LM, Düngen HD, et al. The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure. Wien Klin Wochenschr. 2009;121(9–10):309–313.
    1. Ukena C, Mahfoud F, Kindermann M, et al. The cardiopulmonary continuum systemic inflammation as ‘common soil’ of heart and lung disease. Int J Cardiol. 2010;145(2):172–176.
    1. Curkendall SM, DeLuise C, Jones JK. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16(1):63–70.
    1. global Initiative for Chronic Obstructive Lung Disease Global Strategy for Diagnosis, Management, and Prevention of COPD Updated Feb 2013. Available from: Accessed April 26, 2013
    1. Macchia A, Rodríguez Moncalvo JJ, et al. Unrecognised ventricular dysfunction in COPD. Eur Respir J. 2012;39(1):51–58.
    1. De Blois J, Simard S, Atar D, Agewall S, Norwegian Heart Failure Registry COPD predicts mortality in HF: the Norwegian Heart Failure Registry. J Card Fail. 2010;16(3):225–229.
    1. van der Molen T. Co-morbidities of COPD in primary care: frequency, relation to COPD, and treatment consequences. Prim Care Respir J. 2010;19(4):326–334.
    1. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996;313(7059):711–715.
    1. Hannink JDC, Van Helvoort HAC, Dekhuijzen PNR, Heijdra YF. Heart failure and COPD: partners in crime? Respirology. 2010;15(6):895–901.
    1. Iwamoto H, Yokoyama A, Kitahara Y, et al. Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med. 2009;179(1):35–40.
    1. Eickhoff P, Valipour A, Kiss D, et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;178(12):1211–1218.
    1. Mills NL, Miller JJ, Anand A, et al. Increased arterial stiffnes in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax. 2008;63(4):306–311.
    1. McAllister DA, Maclay JD, Mills NL, et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(12):1208–1214.
    1. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514–1519.
    1. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(12):1259–1265.
    1. Zureik M, Benetos A, Neukirch C, et al. Reduced pulmonary function is associated with central arterial stiffness in men. Am J Respir Crit Care Med. 2001;164(12):2181–2185.
    1. Marin JM, Soriano JB, Carrizo SJ, Boldova A, Celli BR. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea. The overlap syndrome. Am J Respir Crit Care Med. 2010;182(3):325–331.
    1. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107(11):1486–1491.
    1. Steele P, Ellis JH, van Dyke D, Sutton F, Creagh E, Davies H. Left ventricular ejection fraction in severe chronic obstructive airways disease. Am J Med. 1975;59(1):21–28.
    1. Boussuges A, Pinet C, Molenat F, et al. Left atrial and ventricular filling in chronic obstructive pulmonary disease. An echocardiographic and Doppler study. Am J Respir Crit Care Med. 2000;162(2 Pt 1):670–675.
    1. Louie EK, Rich S, Levitsky S, Brundage BH. Doppler echocardiographic demonstration of the differential effects of right ventricular pressure and volume overload on left ventricular geometry and filling. J Am Coll Cardiol. 1992;19(1):84–90.
    1. Gosker HR, Lencer NH, Franssen FM, van der Vusse GJ, Wouters EF, Schols AM. Striking similarities in systemic factors contributing to decreased exercise capacity in patients with severe chronic heart failure or COPD. Chest. 2003;123(5):1416–1424.
    1. Gosker HR, Wouters EF, van der Vusse GJ, Schols AM. Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: underlying mechanisms and therapy perspectives. Am J Clin Nutr. 2000;71(5):1033–1047.
    1. Jondeau G, Katz SD, Zohman L. Active skeletal muscle mass and cardiopulmonary reserve. Failure to attain peak aerobic capacity during maximal bicycle exercise in patients with severe congestive heart failure. Circulation. 1992;86(5):1351–1356.
    1. Harrington D, Anker SD, Chua TP. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol. 1997;30(7):1758–1764.
    1. Jackman RW, Kandarian SC. The molecular basis of skeletal muscle atrophy. Am J Physiol Cell Physiol. 2004;287(4):C834–C843.
    1. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574–580.
    1. Stevenson L, Perloff J. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989;261(6):884–888.
    1. Zeng Q, Jiang S. Update in diagnosis and therapy of coexistent chronic obstructive pulmonary disease and chronic heart failure. J Thorac Dis. 2012;4(3):310–315.
    1. Chhabra SK, Gupta M. Coexistent chronic obstructive pulmonary diseaseheart failure: mechanisms, diagnostic and therapeutic dilemmas. Indian J Chest Dis Allied Sci. 2010;52(4):225–238.
    1. Davie AP, McMurray JJ. Value of ECGs in identifying heart failure due to left ventricular systolic dysfunction. BMJ. 1996;313(7052):300–301.
    1. Boomama F, van der Meiracker AH. Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res. 2001;51(3):442–449.
    1. Tung RH, Camargo CA, Jr, Krauser D, et al. Amino-terminal pro-brain natriuretic peptide for the diagnosis of acute heart failure in patients with previous obstructive airway disease. Ann Emerg Med. 2006;48(1):66–74.
    1. McCullough PA, Hollander JE, Nowak RM, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med. 2003;10(3):198–204.
    1. Al-Mohammad A, Mant J. The diagnosis and management of chronic heart failure: review following the publication of the NICE guidelines. Heart. 2011;97(5):411–416.
    1. Render ML, Weinstein AS, Blaustein AS. Left ventricular dysfunction in deteriorating patients with chronic obstructive pulmonary disease. Chest. 1995;107(1):162–168.
    1. Biernacki W, Flenley DC, Muir AL, MacNee W. Pulmonary hypertension and right ventricular function in patients with COPD. Chest. 1988;94(6):1169–1175.
    1. Devereaux RB, Liebson PR, Horan MJ. Recommendations concerning use of echocardiography in hypertension and general population research. Hypertension. 1987;9(2 Pt 2):II97–II104.
    1. Villar Alvarez F, Méndez Bailón M, de Miguel Díez J. Chronic obstructive pulmonary disease and heart failure. Arch Bronconeumol. 2009;45(8):387–393.
    1. Navarro Esteva J, Alonso B.Insuficiencia cardiaca y enfermedad pulmonar obstructiva crónica. [Heart failure and chronic obstructive pulmonary disease] Arch Med 20051Available from: Accessed February 28, 2013Spanish
    1. Guazzi M, Myers J, Vicenzi M, et al. Cardiopulmonary exercise testing characteristics in heart failure patients with and without concomitant chronic obstructive pulmonary disease. Am Heart J. 2010;160(5):900–905.
    1. Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between β-blocker therapy and outcomes in patients hospitalized with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax. 2012;67(11):977–984.
    1. Dickstein K, Cohen-Solal A, Filippatos G, et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J. 2008;29(19):2388–2442.
    1. Hawkins NM, Petrie MC, MacDonald MR, et al. Heart failure and chronic obstructive pulmonary disease. The quandary of beta-blockers and beta-agonists. J Am Coll Cardiol. 2011;57(21):2127–2138.
    1. Lainscak M, Podbregar M, Kovacic D, Roman J, von Haehling S. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respir Med. 2011;105(Suppl 1):S44–S49.
    1. Mancini GB. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47(12):2554–2560.
    1. Mortensen EM, Copeland LA, Pugh MJ, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45.
    1. Bartziokas K, Papaioannou AI, Minas M, Kostikas K, Banya W, Daniil ZD, et al. Statins and outcome after hospitalization for COPD exacerbation: a prospective study. Pulm Pharmacol Ther. 2011;24(5):625–631.
    1. De Miguel, Díez J, Morán Caicedo L, Rodríguez Rodríguez P, Juarez Morales, MC Puente, Maestu L, Alvarez-Sala Walther L. La enfermedad pulmonar obstructiva crónica como factor de riesgo cardiovascular [COPD as a cardiovascular risk] Aten Primaria. 2012 Mar 5; Epub. Spanish.
    1. Aronow WS. Treatment of heart failure in older persons. Dilemmas with coexisting conditions: diabetes mellitus, chronic obstructive pulmonary disease, and arthritis. Congest Heart Fail. 2003;9(3):142–147.
    1. Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail. 2006;8(7):706–711.
    1. Eshaghian M. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97(12):1759–1764.
    1. O’Kelly N, Robertson W, Smith J, Dexter J, Carroll-Hawkins C, Ghosh S. Short-term outcomes in heart failure patients with chronic obstructive pulmonary disease in the community. World J Cardiol. 2012;4(3):66–71.
    1. Calverley PM, Anderson JA, Celli B, et al. TORCH investigators Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789.
    1. Tashkin DP, Celli B, Senn S, et al. UPLIFT Study Investigators A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554.
    1. Calverley PM, Anderson JA, Celli B, et al. TORCH Investigators Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010;65(8):719–725.
    1. Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest. 2003;123(6):1964–1969.
    1. Souverein DC. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90(8):859–865.
    1. Rialp Cervera G, Del Castillo Blanco A, Pérez Aizcorreta O, Parra Morais L, por el GT-IRA de la SEMICYUC Noninvasive mechanical ventilation in chronic obstructive pulmonary disease and in acute cardiogenic pulmonary edema. Med Intensiva. 2012 Nov 15; Epub. Spanish.
    1. Thorens JB, Ritz M, Reynard C, et al. Haemodynamic and endocrinological effects of noninvasive mechanical ventilation in respiratory failure. Eur Respir J. 1997;10(11):2553–2559.
    1. Masip J, Betbesé AJ, Páez J, Vecilla F, Cañizares R, Padró J, et al. Non-invasive pressure support ventilation versus conventional oxygen therapy in acute cardiogenic pulmonary oedema: a randomised trial. Lancet. 2000;356(9248):2126–2132.
    1. Resterholtz T, Kempf J, Berton C, et al. Noninvasive pressure support ventilation (NIPSV) with face mask in patients with acute cardiogenic pulmonary edema (ACPE) Intensive Care Med. 1999;25(1):21–28.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa